ArticleBMC ophthalmology2025
Characteristics of patients lost to follow-up after intravitreal anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to analyze and compare the characteristics of patients with exudative age-related macular degeneration who were lost to follow-up after receiving intravitreal anti-vascular endothelial growth factor(anti-VEGF) injections versus those who maintained regular follow-up.
methodsThis retrospective study included patients who were lost to follow-up for more than 1 year (n = 79) or maintained follow-up (n = 186) after treatment with intravitreal injections of ranibizumab or aflibercept for exudative age-related macular degeneration. Age, sex, place of residence, type of health insurance, distance from the hospital, laterality of involvement, and follow-up duration were analyzed.
resultsThere were no significant differences between the two groups in terms of age, sex, or type of health insurance. However, patients lost to follow-up resided significantly further from the hospital versus those with regular follow-up (33.1 ± 26.8 vs. 21.6 ± 8.5 km; P = 0.001). A significantly higher proportion of patients that were lost to follow-up had unilateral involvement (P < 0.001) and resided in rural areas (P < 0.001).
conclusionDistance from the hospital, rural residency, and unilateral involvement are significantly associated with nonadherence to follow-up among patients with exudative age-related macular degeneration receiving intravitreal anti-VEGF injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.